NPC's Michael Ciarametaro on How Clinics Can Surmount Gene Therapy Data Collection Barriers

Michael Ciarametaro, MBA, vice president of research at the National Pharmaceutical Council, highlights steps clinics can take to mitigate issues related to data collection regarding cell and gene therapies.

Transcript

What data collection for the purposes of quality measuring is needed to create successful value-based contracts for gene therapies?

Data collection is essential to value-based contracting for gene therapies, and there's both opportunities and challenges related to that. Gene therapies and cell therapies, in general, are unique in the sense that they're administered in these highly specialized clinics, so a lot of them have reporting infrastructure in place, which is a positive.

At the same time, a lot of your existing challenges related to data reporting still exist. How do you track this over a long period of time, and how do you appropriately compensate the physician? There are things that can be done to address those concerns. The first is when you think about the types of outcomes you can collect, you should collect ones that are easy to measure and reliable. The second thing is you need to recognize that physicians need to be appropriately compensated for their time to collect these particular outcomes. And then third, there are market solutions being developed to address some of the patient portability issues in terms of patients moving from one payer to the next.